Literature DB >> 116671

Ferritin, a sensitizing substance in the leucocyte migration inhibition test in patients with malignant lymphoma.

B W Hancock, L Bruce, K May, J Richmond.   

Abstract

The nature of the factor in Hodgkin's disease involved spleen to which many patients with malignant lymphoma react in the leucocyte migration inhibition test has been investigated. Our results suggest that ferritin from Hodgkin's disease involved spleens is antigenically different to that prepared from normal spleen. Isoelectric focusing shows the presence of more acidic 'isoferritins' in ferritin prepared from Hodgkin's disease involved spleen than in that prepared from normal spleen. Further observations using the leucocyte migration inhibition test suggest that sensitization to the abnormal ferritin, acting as an onco-fetal tumour associated substance, may be responsible for the reaction of patients with malignant lymphoma in this test.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 116671     DOI: 10.1111/j.1365-2141.1979.tb03745.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.

Authors:  L Sirota; B Kupfer; C Moroz
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages.

Authors:  H E Broxmeyer; J Bognacki; M H Dorner; M de Sousa
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

Review 3.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

4.  Ferritin-bearing T-lymphocytes and serum ferritin in patients with breast cancer.

Authors:  K Pattanapanyasat; T G Hoy; A Jacobs; S Courtney; D J Webster
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

5.  The British Association for Cancer Research, 23rd annual general meeting. Edinburgh 29--31 March 1982. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.